文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

化生性乳腺癌的全面概述:特征与治疗。

A comprehensive overview of metaplastic breast cancer: Features and treatments.

机构信息

Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin City, Heilongjiang Province, China.

Department of Medical Oncology, Heilongjiang Cancer Prevention and Treatment Institute, Harbin City, Heilongjiang Province, China.

出版信息

Cancer Sci. 2024 Aug;115(8):2506-2514. doi: 10.1111/cas.16208. Epub 2024 May 12.


DOI:10.1111/cas.16208
PMID:38735837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11309924/
Abstract

Metaplastic breast cancer is a rare, aggressive, and chemotherapy-resistant subtype of breast cancers, accounting for less than 1% of invasive breast cancers, characterized by adenocarcinoma with spindle cells, squamous epithelium, and/or mesenchymal tissue differentiation. The majority of metaplastic breast cancers exhibit the characteristics of triple-negative breast cancer and have unfavorable prognoses with a lower survival rate. This subtype often displays gene alterations in the PI3K/AKT pathway, Wnt/β-catenin pathway, and cell cycle dysregulation and demonstrates epithelial-mesenchymal transition, immune response changes, TP53 mutation, EGFR amplification, and so on. Currently, the optimal treatment of metaplastic breast cancer remains uncertain. This article provides a comprehensive review on the clinical features, molecular characteristics, invasion and metastasis patterns, and prognosis of metaplastic breast cancer, as well as recent advancements in treatment strategies.

摘要

化生性乳腺癌是一种罕见的、侵袭性的、对化疗耐药的乳腺癌亚型,占浸润性乳腺癌的比例不到 1%,其特征为具有梭形细胞、鳞状上皮和/或间叶组织分化的腺癌。大多数化生性乳腺癌表现出三阴性乳腺癌的特征,且预后不良,生存率较低。这种亚型常表现出 PI3K/AKT 通路、Wnt/β-catenin 通路和细胞周期失调的基因改变,并表现出上皮-间充质转化、免疫反应变化、TP53 突变、EGFR 扩增等。目前,化生性乳腺癌的最佳治疗方法仍不确定。本文全面综述了化生性乳腺癌的临床特征、分子特征、浸润和转移模式以及预后,并介绍了最近在治疗策略方面的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57e/11309924/9772a4c8099e/CAS-115-2506-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57e/11309924/9772a4c8099e/CAS-115-2506-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57e/11309924/9772a4c8099e/CAS-115-2506-g002.jpg

相似文献

[1]
A comprehensive overview of metaplastic breast cancer: Features and treatments.

Cancer Sci. 2024-8

[2]
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.

Breast Cancer Res. 2020-11-4

[3]
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.

Clin Cancer Res. 2017-7-15

[4]
CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT.

Cancer Res. 2024-10-1

[5]
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].

Mod Pathol. 2015-3

[6]
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.

World J Surg Oncol. 2020-1-14

[7]
Clinicopathological features of metaplastic breast carcinoma.

Adv Clin Exp Med. 2018-4

[8]
Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.

Mod Pathol. 2018-6-26

[9]
Metaplastic breast cancer: Prognostic and therapeutic considerations.

J Surg Oncol. 2021-1

[10]
Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.

Clin Breast Cancer. 2017-4-26

引用本文的文献

[1]
An anaplastic ependymoma with chondroid metaplasia after stereotactic radiosurgery: illustrative case.

J Neurosurg Case Lessons. 2025-8-4

[2]
Rare Breast Cancers Review.

Healthcare (Basel). 2024-12-9

本文引用的文献

[1]
Germline pathogenic variants in metaplastic breast cancer patients and the emerging role of the BRCA1 gene.

Eur J Hum Genet. 2023-11

[2]
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.

NPJ Breast Cancer. 2023-6-21

[3]
Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study.

EClinicalMedicine. 2023-3-24

[4]
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.

J Clin Oncol. 2023-4-1

[5]
RHOJ controls EMT-associated resistance to chemotherapy.

Nature. 2023-4

[6]
Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis.

Cancers (Basel). 2023-3-2

[7]
Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.

Breast Cancer Res. 2023-1-27

[8]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[9]
TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.

Histopathology. 2023-4

[10]
The Effect of HER2 Status on Metaplastic Breast Cancer A Propensity Score-Matched Analysis.

Front Endocrinol (Lausanne). 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索